William Chou

Chief Executive Officer at PASSAGE BIO, INC.

Net worth: - $ as of 30/03/2024

51 year

Consumer Services

Health Technology

Profile

William Chou is currently the President, Chief Executive Officer & Director at Passage Bio, Inc. Prior to his current position, he served as the Chief Executive Officer at Aruvant Sciences, Inc. Dr. Chou completed his undergraduate degree at Princeton University, followed by an MBA from Yale School of Management.
He also holds a doctorate degree from the University of Pittsburgh School of Medicine.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
PASSAGE BIO, INC. -.--%	17/03/2024	0 ( -.--% )	- $	30/03/2024

William Chou active positions

Companies	Position	Start
PASSAGE BIO, INC.	Chief Executive Officer	09/10/2022

All active positions of William Chou

Former positions of William Chou

Companies	Position	End
Aruvant Sciences, Inc. Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY.	Chief Executive Officer	-

See the detail of William Chou's experience

Training of William Chou

Princeton University	Undergraduate Degree
Yale School of Management	Masters Business Admin
University of Pittsburgh School of Medicine	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of William Chou's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
PASSAGE BIO, INC.	Health Technology

Private companies	1
Aruvant Sciences, Inc. Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY.	Health Technology